^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Mucosal Melanoma

    Related cancers:
    4d
    A Rare Case of Aggressive Tongue Malignant Melanoma: Clinical Presentation and Treatment Approach. (PubMed, Cureus)
    A multidisciplinary approach combining radical surgery and adjuvant RT is crucial; however, the rapid distant progression highlights the critical need for more effective systemic treatment options and the integration of genetic profiling to guide personalized therapies. Further comprehensive research is essential to optimize management strategies and improve the limited survival outcomes associated with this rare and challenging malignancy.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    5d
    Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma (clinicaltrials.gov)
    P1/2, N=8, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Oct 2025 --> Aug 2026
    Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Inqovi (decitabine/cedazuridine)
    15d
    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma (clinicaltrials.gov)
    P2, N=19, Recruiting, Washington University School of Medicine | Trial completion date: Feb 2029 --> Jul 2032 | Trial primary completion date: Feb 2027 --> Jul 2030
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    15d
    Rac1 signaling-associated genes are upregulated in nodal metastasis of canine oral mucosal melanoma. (PubMed, Vet Pathol)
    Overall, the results of this investigation point to a significant role for Rac1 signaling in the pathogenesis of OMM metastasis to regional lymph nodes. The Rac1 signaling-associated genes highlighted herein are indeed involved in the activation of cellular migration, and one, or more, may represent a future therapeutic target to prevent metastatic dissemination, or treat OMM with distant metastases.
    Journal
    |
    NODAL (Nodal Growth Differentiation Factor)
    16d
    Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib. (PubMed, J Clin Med)
    Despite substantial advances, secondary mutations and reactivation of oncogenic signaling remain major challenges. This narrative review integrates data from clinical, preclinical, and real-world studies to update the current understanding of targeted therapies in cutaneous melanoma and highlight ongoing research aimed at overcoming resistance and optimizing personalized treatment strategies.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    BRAF V600E
    |
    Mekinist (trametinib) • Zelboraf (vemurafenib) • imatinib
    17d
    KEYNOTE-B77: BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (clinicaltrials.gov)
    P2, N=42, Completed, Highlight Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • polyinosinic:polycytidylic acid (BO-112)
    17d
    Comparative Insights into Cutaneous, Mucosal, and Vulvovaginal Melanomas: Biology, Targeted Therapies, and Survival with a Focus on Immune Checkpoint Inhibitors. (PubMed, J Pers Med)
    Mucosal and vulvovaginal melanomas are biologically and clinically distinct from cutaneous melanoma and continue to have poor survival outcomes. Their rarity restricts high-quality evidence, highlighting the need for collaborative, innovative research to inform effective treatment strategies.
    Review • Journal • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    TMB-H • BRAF mutation • NRAS mutation • TMB-L
    21d
    APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=34, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; <75% participant accrual
    Trial termination
    |
    Keytruda (pembrolizumab) • sotigalimab (PYX-107)
    23d
    Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (clinicaltrials.gov)
    P2, N=531, Not yet recruiting, Melanoma Institute Australia | N=297 --> 531 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2027 --> Dec 2027
    Enrollment change • Trial initiation date • Trial primary completion date • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    24d
    Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    26d
    A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, BeiGene | N=202 --> 113 | Trial primary completion date: Oct 2026 --> May 2025
    Enrollment change • Trial primary completion date
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • BGB-A445
    26d
    NEOREM-NEO-1: Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, UNICANCER
    New P2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)